

PRESS RELEASE

Lund April 23, 2020

Tumorad[®] patent approval in Japan

Spago Nanomedical has received notice of allowance for the company's patent application including Tumorad[®] product protection in Japan.

"The patent covers the nanomaterial that is central for the Tumorad[®]-project. As Japan represent a potentially large market for radionuclide therapies, this approval is important. It also underscores the quality of our innovation and strengthens the commercial prospects of the project", says Spago Nanomedical CEO Mats Hansen.

The patent, titled "Nanostructures and applications thereof" (application no. 2017-501494), is valid until 2035.

With the approval Spago Nanomedical holds product protection for Tumorad[®] in the largest markets for radionuclide therapy. Patent protection has previously been granted in several strategically important regions, including the USA and EU.

Tumorad[®] is a new type of radionuclide therapy based on Spago Nanomedical's proprietary material and a therapeutically relevant radioisotope for tumor selective radiation therapy of cancer.

Access to new therapies is essential for effective treatment of many forms of cancer. Tumorad[®] holds potential for treatment of aggressive and metastatic tumors, as monotherapy or in synergy with other treatment types. Currently an extensive program for documentation of proof of concept is ongoing in preparation for preclinical safety studies and clinical trials.

For further information, please contact Mats Hansen CEO Spago Nanomedical AB, +46 46 81188, mats.hansen@spagonanomedical.se.

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company's development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical's share is listed on Spotlight Stock Market in Stockholm (ticker: SPAG).

For further information, see www.spagonanomedical.se.

The information in this press release is such that Spago Nanomedical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU, 596/2014). The information was submitted for publication, through the agency of the contact person set out above, on April 23, 2020.